SIETES :: 92751 citas

Resultados de la búsqueda por DOLOR DE CABEZA REFINAR BÚSQUEDA

1.

Haight BR, Learned SM, Lafont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Linq W, Heidbreder C, RB-US-13-0001 Study Investigators. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393:23 de febrero. [Ref.ID 103111]

2.

Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. FDA U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]

3.

Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department. A randomized clinical trial. JAMA 2017;318:1661-7. [Ref.ID 102137]

4.

Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD, for the CHAMP Investigators. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med 2017;376:115-24. [Ref.ID 101371]

5.

Amundsen S, Ovrebo TG, Amble NMS, Poole AC, Nordeng H. Use of antimigraine medications and information needs during pregnancy and breastfeeding: a cross-sectional study among 401 Norwegian women. Eur J Clin Pharmacol 2016;72:1525-35. [Ref.ID 101013]

6.

Anónimo. Aducanumab shows encouraging results as Alzheimer’s treatment in early clinical trial. DIA Daily 2016:3. [Ref.ID 100617]

7.

Anónimo. FDA approves Epclusa for treatment of chronic hepatitis C virus infection. FDA U.S. Food and Drug Administration 2016:28 de junio. [Ref.ID 100447]

8.

Anonimo. Zecuity (sumatriptan) migraine patch: Drug Safety Communication - FDA evaluating risk of burns and scars. FDA MedWatch alert 2016:2 de junio. [Ref.ID 100411]

9.

Anónimo. Zecuity (sumatriptan) migraine patch: Drug Safety Communication - FDA evaluating risk of burns and scars. FDA U.S. Food and Drug Administration 2016:2 de junio. [Ref.ID 100357]

10.

Wong J, Motulsky A, Eguale T, Buckeridge DL, Abrahamowicz M, Tamblyn R. Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006-2015. JAMA 2016;315:2230-2. [Ref.ID 100316]

11.

Wood ME, Frazier JA, Nordeng HME, Lapane KL. Prenatal triptan exposure and parent-reported early childhood neurodevelopmental outcomes: an application of propensity score calibration to adjust for unmeasured confounding by migraine severity. Pharmacoepidemiol Drug Saf 2016;25:493-502. [Ref.ID 100261]

12.

Anónimo. FDA approves new orphan drug to treat pulmonary arterial hypertension. FDA U.S. Food and Drug Administration 2015:22 de diciembre. [Ref.ID 99740]

13.

Anónimo. FDA approves Nucala to treat severe asthma. FDA U.S. Food and Drug Administration 2015:4 de noviembre. [Ref.ID 99610]

14.

Meltzer EO, Ratner PH, McGraw T. Oral phenylephrine HCl for nasal congestion in seasonal allergic rhinitis: a randomized, open-label, placebo-controlled study. J Allergy Clin Immunol 2015;3:702-8. [Ref.ID 99480]

15.

Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 2015:14 de julio. [Ref.ID 99455]

16.

Hawkes N. Modafinil does enhance cognition, review finds. BMJ 2015;351:h4573. [Ref.ID 99412]

17.

Dear JW, Antoine DJ, Park BK. Where are we now with paracetamol?. BMJ 2015;351:h3705. [Ref.ID 99251]

18.

Anónimo. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. FDA U.S. Food and Drug Administration 2014:1. [Ref.ID 98380]

19.

Tan K, Petrie KJ, Faasse K, Bolland MJ, Grey A. Unhelpful information about adverse drug reactions. BMJ 2014;349:g5019. [Ref.ID 98190]

20.

Anónimo. Another hepatitis C treatment recieves FDA approval. DIA Daily 2014:13 de octubre. [Ref.ID 98033]